SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,631.64 |
Enterprise Value ($M) | 1,568.23 |
Book Value ($M) | 929.17 |
Book Value / Share | 16.90 |
Price / Book | 1.76 |
NCAV ($M) | 169.40 |
NCAV / Share | 3.08 |
Price / NCAV | 9.63 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.02 |
Return on Assets (ROA) | -0.01 |
Return on Equity (ROE) | -0.02 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.49 |
Current Ratio | 1.73 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 544.32 |
Assets | 1,304.09 |
Liabilities | 374.92 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 607.52 |
Operating Income | 13.40 |
Net Income | 1.32 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 111.08 |
Cash from Investing | 268.73 |
Cash from Financing | -397.88 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 8.51 | 6.75 | |
13G | Macquarie Group Ltd | 5.01 | ||
13G/A | Vanguard Group Inc | 11.38 | 7.34 | |
13G/A | BlackRock Inc. | 19.00 | 8.09 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
45,875 | 501,711 | 9.14 | |
92,353 | 549,388 | 16.81 | |
198,091 | 922,410 | 21.48 | |
215,871 | 373,581 | 57.78 | |
(click for more detail) |
Similar Companies | |
---|---|
SNSE – Sensei Biotherapeutics, Inc. | SPRY – ARS Pharmaceuticals, Inc. |
STRO – Sutro Biopharma, Inc. | TARA – Protara Therapeutics, Inc. |
TBPH – Theravance Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io